Navidea Biopharmaceuticals, Inc.

Navidea Biopharmaceuticals, Inc. is currently assessed as overvalued with significant financial concerns, reflected in its negative price-to-book value and poor market performance, despite a misleadingly high return on capital employed.

As of June 3, 2025, Navidea Biopharmaceuticals, Inc. shows a mildly bearish trend with daily moving averages indicating weakness, despite some mildly bullish signals from weekly MACD and RSI, amidst a lack of strong trends in other indicators.

As of March 2022, the management team of Navidea Biopharmaceuticals, Inc. includes Independent Chairman Mr. Y. Michael Rice, Directors Mr. Malcolm Witter, Dr. Claudine Bruck, Mr. Adam Cutler, and Dr. S. Kathryn Rouan, who oversee the company's strategic direction and governance.

Navidea Biopharmaceuticals, Inc. is a micro-cap biopharmaceutical company focused on developing precision immunodiagnostic agents and immunotherapeutics. As of September 2023, it reported a net profit loss of $2 million and has a market cap of $0.07 million.

As of Jun 18, Navidea Biopharmaceuticals, Inc. has a market capitalization of 0.07 million, with net sales of 0.00 million and a consolidated net profit of -8.61 million over the latest four quarters. As of Dec'22, shareholder's funds were -8.44 million, and total assets were 4.37 million.